BC
BCRX.O
—
NASDAQ
Biotechnology
BioCryst Pharmaceuticals Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
39,0 %
ROE
-221,5 %
Net margin
30,2 %
Debt / equity
-0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$9,34
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
BioCryst Pharmaceuticals Inc operates as a biotechnology company within the Health Care sector, generating revenue through the development and commercialization of pharmaceutical products.
Business. BioCryst Pharmaceuticals Inc (BCRX.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level as a biotechnology entity.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
-221,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,4 %−2,7 %−0,9 %
Real Estate−0,7 %+10,9 %−1,3 %
Consumer Staples−0,7 %+2,3 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to BCRX.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJosh Gottheimer — BioCryst Pharmaceuticals, Inc.2023-10-16 · Democrat · NJ · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — BioCryst Pharmaceuticals, Inc.2023-09-15 · Democrat · NJ · Sale · $1,001 - $15,000
- CongressJosh Gottheimer — BioCryst Pharmaceuticals, Inc.2022-08-11 · Democrat · NJ · Purchase · $1,001 - $15,000
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
BioCryst Pharmaceuticals Inc (BCRX.O) is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level as a biotechnology entity.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDBioCryst Pharmaceuticals maintains a negative equity position of -119.2 million USD against total liabilities of 633.3 million USD and total assets of 514.2 million USD. The company holds 89.7 million USD in cash and equivalents with zero long-term debt, resulting in a debt-to-equity ratio of -0.0. Operating cash flow stands at 347.4 million USD, significantly exceeding capital expenditures of 2.5 million USD, which supports the low liquidity risk assessment despite the negative book equity.
Profitability metrics show a return on assets of 0.51 and a negative return on equity of -2.21, reflecting the negative equity base. Net income is reported at 263.9 million USD on revenue of 874.8 million USD, indicating strong operating leverage with operating income of 341.0 million USD. Without cohort median data for direct comparison, the absolute margins suggest efficient cost management relative to revenue generation.
Segment and geographic revenue breakdowns are not provided in the available data. The company operates through several subsidiaries including Astria Therapeutics, Quellis Biosciences, and international entities in Canada and Japan, suggesting a diversified operational structure, but specific revenue concentration risks cannot be quantified from the current input.
Historical growth trajectory data is absent from the provided financial periods. The current snapshot shows a single period of revenue and net income, preventing trend analysis or year-over-year growth calculations. The company’s ability to sustain current profitability levels over time remains unverified by historical data in this input.
Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The negative equity position is a structural flag, but the absence of long-term debt and strong operating cash flow mitigate immediate solvency concerns. Dilution risk is further supported by the equality of basic and diluted shares outstanding at 213.1 million.
Recent observations include internal reconciler events for analysis job queuing, with no significant external news, filing, or transcript events disclosed. The company’s subsidiary structure is well-documented through EX-21 filings, confirming the existence of multiple domestic and international operating entities.
Key takeaways
- Negative equity of -119.2 million USD is offset by zero long-term debt and 89.7 million USD in cash.
- Operating cash flow of 347.4 million USD exceeds net income of 263.9 million USD, indicating strong cash conversion.
- Return on assets of 0.51 demonstrates efficient asset utilization despite negative book equity.
- Low dilution risk is confirmed by matching basic and diluted share counts of 213.1 million.
- No historical trend data is available to assess revenue or profit growth trajectories.
- Subsidiary network includes international operations in Canada and Japan, suggesting global reach.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$8,91
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$119.2M
Net cashⓘ
$89.7M
Current ratioⓘ
—
Debt / equityⓘ
-0.0
ROAⓘ
51.3%
ROEⓘ
-2.2%
Cash conversionⓘ
132.0%
CapEx / revenueⓘ
0.3%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships11 disclosed relationships · 2 types · extracted from filings & disclosures
Partners3
Kaken Pharmaceutical Co Ltd4521.TPartner95%Source ↗
Neopharm Co Ltd092730.KQPartner95%Source ↗
Shionogi & Co Ltd4507.TPartner95%Source ↗
Subsidiaries8
EX21:17f5da1e8c07EX21:17f5da1e8c07Subsidiarie97%
EX21:23d86ac7bf67EX21:23d86ac7bf67Subsidiarie97%
EX21:64b38c44f469EX21:64b38c44f469Subsidiarie97%
EX21:675422626f9dEX21:675422626f9dSubsidiarie97%
EX21:92bcf413ed4fEX21:92bcf413ed4fSubsidiarie97%
EX21:a866e151d41bEX21:a866e151d41bSubsidiarie97%
EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%
EX21:de4f5e53b21bEX21:de4f5e53b21bSubsidiarie97%
Supply chain
Vendors → BCRX ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution11 analysts
Strong buy3
Buy7
Hold1
Sell0
Strong sell0
12-month price target$21,80 · Median $19,00
Low $13,00High $32,00
Operating income · consensus-593,6M USD
EPS surprise
+103,6 %
reported vs consensus · beat
Revenue surprise
−5,3 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$13,00
Mean$21,80
Median$19,00
High$32,00
Spot$8,91
+144.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin39,0 %Above P75
Net Margin30,2 %Above P75
ROE-221,5 %Bottom quartile
Capex / Rev0,3 %Above median
D/E-0,00Above median
Cash Conv1,32Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 174 782 sh4 exercises · 10 grants11 insiders
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Director · Automatic Stock Option Grant → Common StockAcquired 33 540 @ $8,50grant · 2026-06-11
- Chief Legal Officer · Emp. Stock Option (Right to Buy) → Common StockDisposed 62 500 @ $5,04exercise · 2026-05-13
- Chief R&D Officer · Emp. Stock Option (Right to Buy) → Common StockAcquired 441 350 @ $9,47grant · 2026-04-06
- Director · Automatic Stock Option Grant → Common StockDisposed 49 933 @ $6,30exercise · 2026-03-20
- Chief Legal Officer · Emp. Stock Option (Right to Buy) → Common StockDisposed 150 000 @ $5,51exercise · 2026-03-16
- Director · Emp. Stock Option (Right to Buy) → Common StockDisposed 305 995 @ $3,22exercise · 2026-03-02
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Equitynet_income / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
Source documents
- BIOCRYST PHARMACEUTICALS, INC. Market data — financials · 2026-07-27
- reconciler_enqueue (reconciler) on BCRX.O · 2026-07-27
- BioCryst Pharmaceuticals Inc HA canonical relationships · 2026-07-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,04 %$85M
- Investment Managers · as of 2026-03-310,01 %$26M
- Investment Managers · as of 2026-03-310,01 %$47M
- Investment Managers · as of 2024-12-310,01 %$26M
- Investment Managers · as of 2026-03-310,01 %$8M
- Investment Managers · as of 2026-03-310,01 %$26M
- Investment Managers · as of 2026-03-310,00 %$116M
- Investment Managers · as of 2026-03-310,00 %$55M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2024-06-300,00 %$123M
- Investment Managers · as of 2026-03-310,00 %$20M
- Investment Managers · as of 2025-12-310,00 %$174M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$4M
- Funds · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$19M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Jon P. StonehousePresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 4 sellsnet -$2,6M11 insiders · last 365d
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 15 294 · 2026-06-11
- Director · Common StockOther 631 @ $8,91$6K · 2026-05-29
- Director · Common StockOther 1 262 @ $8,91$11K · 2026-05-29
- Director · Common StockOther 1 122 @ $8,91$10K · 2026-05-29
- Director · Common StockOther 631 @ $8,91$6K · 2026-05-29
- Director · Common StockOther 1 262 @ $8,91$11K · 2026-05-29
- Director · Common StockSold 11 180 @ $8,97$100K · 2026-05-18
- Chief Legal Officer · Common StockSold 62 500 @ $9,54$596K · 2026-05-13
- Chief Legal Officer · Common StockOther 62 500 @ $5,04$315K · 2026-05-13
- Chief R&D Officer · Common StockOther 205 150 · 2026-04-06
- Director · Common StockOther 49 933 @ $6,30$315K · 2026-03-20
- Director · Common StockSold 49 933 @ $10,11$505K · 2026-03-20
- Chief Legal Officer · Common StockOther 150 000 @ $5,51$826K · 2026-03-16
- Chief Legal Officer · Common StockSold 150 000 @ $9,15$1,4M · 2026-03-16
- Director · Common StockOther 305 995 @ $3,22$985K · 2026-03-02
- Director · Common StockOther 305 995 @ $8,64$2,6M · 2026-03-02
- Director · Common StockOther 642 @ $8,75$6K · 2026-02-27
Short positioning
31.2Mshares short-35.9% vs prior
5.95days to cover
48.9%short of daily vol
400fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
BCRX.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- Total liabilities (annual): USD 633.31MUnknown
- Long-term debt (annual): USD 0Unknown
- EPS (diluted) (annual): USD-PER-SHARES 1Unknown
- Shareholders' equity (annual): USD -119.15MUnknown
- Total assets (annual): USD 514.16MUnknown
- Current assets (annual): USD 404.35MUnknown
- Current liabilities (annual): USD 196.07MUnknown
- Cash & equivalents (annual): USD 89.74MUnknown
- Net income (annual): USD 263.86MUnknown
- Cost of revenue (annual): USD 19.07MUnknown
- Operating income (annual): USD 340.99MUnknown
- Shares outstanding (annual): 213.06MUnknown
- EPS (basic) (annual): USD-PER-SHARES 1Unknown
- R&D expense (annual): USD 166.13MUnknown
- Operating cash flow (annual): USD 347.37MUnknown
- Pre-tax income (annual): USD 267.39MUnknown
- Cost of revenue (annual): USD 12.27MUnknown
- Net income (annual): USD -88.88MUnknown
- Operating income (annual): USD -2.54MUnknown
- Current assets (annual): USD 421.97MUnknown
- Operating cash flow (annual): USD -52.02MUnknown
- Cash & equivalents (annual): USD 104.71MUnknown
- Total assets (annual): USD 490.42MUnknown
- Shares outstanding (annual): 208.54MUnknown
Showing 24 of 32 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-05 00:00 UTCTRANSCRIPTUpcomingEarnings call — Q3 2026
2026-06-11 00:00 UTCINSIDER18 insider transactions — 2026-06 9 derivative
2026-06-11 00:00 UTCINSIDER18 insider transactions — 2026-06 9 derivative
2026-06-11INSIDERSANDERS MACHELLE transacted 15.3k sh — Director
2026-06-11INSIDERFrank Steven transacted 15.3k sh — Director
2026-06-11INSIDERMILANO VINCENT transacted 15.3k sh — Director
2026-06-11INSIDERStonehouse Jon P transacted 15.3k sh — Director
2026-06-11INSIDERHEGGIE THERESA transacted 15.3k sh — Director
2026-06-11INSIDERMcKee Amy E transacted 15.3k sh — Director
2026-06-11INSIDERMilne Jill C. transacted 15.3k sh — Director
2026-06-11INSIDERGalson Steven K transacted 15.3k sh — Director
2026-06-11INSIDERLEVIN ALAN G transacted 15.3k sh — Director
2026-06-11INSIDERGalson Steven K acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERLEVIN ALAN G acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERMilne Jill C. acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERHEGGIE THERESA acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERMcKee Amy E acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERStonehouse Jon P acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERMILANO VINCENT acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERSANDERS MACHELLE acquired 33.5k sh Automatic Stock Option Grant — Director
2026-06-11INSIDERFrank Steven acquired 33.5k sh Automatic Stock Option Grant — Director
2026-05-29 00:00 UTCINSIDER9 insider transactions — 2026-05 · net sell $338k 1 derivative
2026-05-29 00:00 UTCINSIDER9 insider transactions — 2026-05 · net sell $338k 1 derivative
2026-05-29INSIDERStonehouse Jon P transacted 631 sh — Director ~$6k
2026-05-29INSIDERFrank Steven transacted 1.3k sh — Director ~$11k
2026-05-29INSIDERMILANO VINCENT transacted 1.1k sh — Director ~$10k
2026-05-29INSIDERMcKee Amy E transacted 631 sh — Director ~$6k
2026-05-29INSIDERMilne Jill C. transacted 1.3k sh — Director ~$11k
2026-05-18INSIDERMcKee Amy E sold 11.2k sh — Director ~$100k
2026-05-13INSIDERBarnes Alane P sold 62.5k sh — Chief Legal Officer ~$596k
2026-05-13INSIDERBarnes Alane P transacted 62.5k sh — Chief Legal Officer ~$315k
2026-05-13INSIDERBarnes Alane P disposed of 62.5k sh Emp. Stock Option (Right to Buy) — Chief Legal Officer
2026-04-06 00:00 UTCINSIDER2 insider transactions — 2026-04 1 derivative
2026-04-06 00:00 UTCINSIDER2 insider transactions — 2026-04 1 derivative
Showing the 40 most recent of 63 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage